MotherToBaby

Medications and More during pregnancy and breastfeeding

Buscar

866.626.6847

Mifepristone

Selected References:

  • Auffret M, et al. 2016. Misoprostol exposure during the first trimester of pregnancy: Is the malformation risk varying depending on the indication? Eur J Obstet Gynecol Reprod Biol, 207:188-192.
  • Baev OR, et al. 2017. Outcomes of mifepristone usage for cervical ripening and induction of labour in full-term pregnancy. Randomized controlled trial. Eur J Obstet Gynecol Reprod Biol, 217:144-149.
  • Brown A, et al. 2002. Daily low dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomised controlled trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab, 87:63-70.
  • Bos-Thompson MA, et al. 2008. Mobius syndrome in a neonate after mifepristone and misoprostol elective abortion failure. Ann Pharmacother, 42(6):888-892.
  • Chen A, et al. 2004. Mifepristone-induced early abortion and outcome of subsequent wanted pregnancy. Am J Epidemiol, 160(2):110-117.
  • Gary MM, Harrison DJ. 2006. Analysis of severe adverse events related to the use of mifepristone as an abortifacient. Ann Pharmacother, 40:191-197.
  • Glasier A, et al. 1992. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. N Engl J Med, 327:1041-1044.
  • Juneja SC, Dodson MG. 1990. In vitro effect of RU 486 on sperm-egg interaction in mice. Am J Obstet Gynecol, 163:216-221.
  • Lakha F, et al. 2007. A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum Reprod, 22(9):2428-2436.
  • Liao H, et al. 2011. Repeated medical abortions and the risk of preterm birth in the subsequent pregnancy. Arch Gynecol Obstet, 284(3):579-586.
  • Lim BH, et al. 1990. Normal development after exposure to mifepristone in early pregnancy. Lancet, 336:257-258.
  • Mifepristone Drug Label. 2023. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b63fad9b-7f12-4400-9019-b0586054e534.
  • Peyron R, et al. 1993. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med, 328:1509-1513.
  • Pons JC, et al. 1991. Development after exposure to mifepristone in early pregnancy. Lancet; 338:763.
  • Saav I, et al. 2010. Medical abortion in lactating women–low levels of mifepristone in breast milk. Acta Obstet Gynecol Scand, 89(5):618-622.
  • Sanchez-Criado JE, et al. 1990. A possible dual mechanism of the anovulatory action of antiprogesterone RU486 in the rat. Biol Reprod, 42:877-886.
  • Shoupe D, et al. 1987. Effects of the antiprogesterone RU 486 in normal women. II. Administration in the late follicular phase. Am J Obstet Gynecol, 157:1421-1426.
  • Sitruk-Ware R, Davey A, Sakiz E. 1998. Fetal malformations and failed medical termination of pregnancy. Lancet, 352:323.
  • Swahn ML, et al. 1996. Contraception with anti-progesterone. Baillieres Clin Obstet Gynaecol, 10(1):43-53.
  • Task force on postovulatory methods of fertility regulation. 1999. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet 353:607-702.
  • van der Schoot P, et al.1987. Effects of the progesterone antagonist RU486 on ovarian activity in the rat. Endocrinology, 121:1375-1382.
  • Wolf JP. et al. 1990. Tolerance of perinidatory primate embryos to RU 486 exposure in vitro and in vivo. Contraception, 41:85-92.
  • Yang YQ, Wu JT. 1990. RU 486 interferes with egg transport and retards the in vivo and in vitro development of mouse embryos. Contraception, 41:551-556.
  • Zhu QX, et al. 2009. Mifepristone-induced abortion and placental complications in subsequent pregnancy. Hum Reprod, 24(2):315-319.

MotherToBaby cuenta con el apoyo de la Administración de Recursos y Servicios de Salud (HRSA) del Departamento de Salud y Servicios Humanos de los Estados Unidos (HHS) como parte de una adjudicación por un total de $6,000,000 con cero porcentaje financiado con fuentes no gubernamentales. Los contenidos son los del autor/es y no representan necesariamente los puntos de vista oficiales de, ni un respaldo, por HRSA, HHS o el Gobierno de los Estados Unidos.